FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam

The FDA ap­proved Bridge­Bio’s ​​aco­ramidis in a rare, ge­net­ic heart dis­ease that’s ex­pect­ed to be­come an in­tense area of mar­ket com­pe­ti­tion, and a broad la­bel … Sign up to read … Read More